Agentic AI in Clinical Trials: How Maxis AI’s Agents are Driving Evolution
What is Maxis AI – and why is it redefining the future of clinical trials?
In this episode, we explore the rise of Agentic AI and how Maxis AI is pioneering its application in clinical research. Join Nicole Powell, Senior Vice President at Maxis AI, and Moulik Shah, CEO & Founder of Maxis AI, as they answer the most frequently asked questions from clinical operations, data management, and R&D teams.
Discover how AI agents—built for purpose and powered by context—are enabling trial teams to go beyond traditional automation, with intelligent systems that adapt, prioritize, and act across a robust clinical data ecosystem.
Whether you are evaluating where to start or looking to scale AI across studies and therapeutic areas, this episode offers actionable insights grounded in real-world experience.
Key Takeaways
- What is Agentic AI and how it differs from traditional automation and generative AI.
- What sets Maxis AI’s AI agents apart—thanks to its end-to-end platform, industry experience, and early AI adoption (pre-COVID).
- Debunking common myths: AI bias, lack of human oversight, explainability, and misconceptions about scalability.
- Top challenges in scaling AI agents across therapeutic areas—and how a strong data foundation makes it possible.
- Where clinical teams should start the AI journey and what realistic adoption timelines look like.
Meet the Guests
Moulik Shah
CEO & Founder, Maxis AI.
Moulik Shah has been at the forefront of leveraging technology to transform pharmaceutical and life sciences clinical trials for over 20 years. A passionate healthcare technology entrepreneur, Moulik’s dedication to improving clinical outcomes has fueled his vision of an integrated healthcare ecosystem based on effective use of data and analytics platforms.
Moulik has been instrumental in driving innovation and progress in industry. Under his leadership, Maxis AI has become a leading provider of clinical data and analytics, driving real-world impact in the pharmaceutical and life sciences clinical trials.
Nicole Powell
Senior Vice President, Business Development, Maxis AI.
Nicole, a strategic leader with over 17 years of experience in the clinical research industry, has consistently driven transformative revenue growth across diverse markets. Her expertise lies in building strong partnerships and steering corporate strategies that align with evolving industry needs. At Maxis AI, Nicole is excited to bring her insights and passion for collaboration to expand the reach of Maxis AI’s Clinical Data Analytics Platform, helping clients streamline trials and achieve their objectives.
Nicole recently led business development and marketing at SDC, where she pioneered growth initiatives and contributed to shaping the future of clinical trial technology. An experienced speaker, Nicole has presented at numerous industry conferences on tech-driven innovation in clinical research. She holds a BA from the University of Texas San Antonio and an MBA from Baylor University. Based in Virginia, Nicole enjoys golfing, exploring new destinations, and karaoke in her free time.
Want to See Agentic AI in Action?
Maxis AI’s agentic AI platform is helping global clinical teams make faster, more confident decisions.
About Maxis AI
Maxis AI (formerly MaxisIT) is focused on transforming drug development through the power of intelligent technology. With its forward-thinking “Maxis AI – Drug Development Agency” model and its Intelligent Platform “Designed to Think. Built to Act.,” the company helps pharmaceutical, and life sciences organizations achieve smarter, faster insights and more effective processes for superior clinical outcomes. Drawing on over 20 years of industry experience and a comprehensive suite of solutions, Maxis AI is committed to accelerating the delivery of life-saving therapies. Headquartered in Edison, NJ, Maxis AI is committed to innovation, precision, and integrity in advancing clinical trials. Explore the future of clinical development at www.maxisai.com.
